Early investigations of RET in breast cancer were primarily focused on estrogen receptor-alpha-positive (ER+) cases due to the prevalent co-overexpression of RET and its co-receptor, GFRα1, in a subset of ER+ breast cancers (142). The gene discussed is GFRA1; the disease is breast carcinoma.